Cancer cachexia mechanism links iron to fat wasting

A cancer cachexia mechanism identified in a new Nature Cancer study begins in an unexpected place: iron metabolism inside fat cells. In mouse models of pancreatic cancer, an iron-dependent enzyme helped turn white adipose tissue into a more energy-consuming state. Removing that enzyme preserved fat and muscle and extended the animals' survival.

Cachexia is a severe wasting syndrome seen in many people with advanced cancer. Patients lose body weight, adipose tissue and skeletal muscle, and simply providing additional calories often does not reverse the process.

In pancreatic ductal adenocarcinoma, adipose loss can precede substantial muscle wasting. That led the researchers to focus on the changes occurring in fat tissue early in cachexia.

Their experiments uncovered a signaling chain connecting sympathetic stimulation, iron uptake, the enzyme methionine sulfoxide reductase A (MSRA), protein kinase A and increased energy expenditure.

When stored fat begins consuming more energy

White adipose tissue normally functions mainly as an energy reservoir. Under certain conditions, however, white adipocytes can acquire features normally associated with thermogenic brown fat, including increased mitochondrial activity and greater conversion of chemical energy into heat.

This process is known as white adipose tissue browning.

In a physiological setting such as cold exposure, thermogenesis is useful. During cachexia, sustained thermogenic remodeling can have the opposite consequence: an organism already losing mass spends more of its stored energy.

The researchers first studied genetically engineered mice that develop pancreatic ductal adenocarcinoma. Their white adipose tissue showed hallmarks of browning, including smaller lipid droplets, increased mitochondrial activity and induction of thermogenic proteins.

Human tissue showed a similar pattern. Visceral adipose specimens from people with pancreatic cancer and cachexia contained smaller adipocytes, more mitochondria and increased MSRA expression. One morphological comparison included tissue from 14 patients with cachectic pancreatic cancer and six people without tumors.

Those human samples establish an association rather than causation. The experiments that tested the pathway directly were performed mainly in cells and mouse models.

Iron activates a molecular switch

Thermogenic adipocytes require substantial mitochondrial machinery, much of which depends on iron-containing proteins. The investigators found increased iron uptake in white adipose tissue during tumor-associated browning.

Iron did more than support mitochondrial metabolism.

It bound directly to MSRA, an enzyme that normally reverses the oxidation of methionine residues in proteins. The study showed that iron promotes the association of two MSRA molecules, stabilizing the protein and increasing its reductase activity.

One of the relevant MSRA targets was the catalytic subunit of protein kinase A, or PKA, a key component of adrenergic signaling in adipocytes.

Oxidation of a specific methionine residue in PKA reduced its ability to bind ATP and function efficiently. MSRA restored that methionine to its reduced state, helping maintain PKA activity.

The pathway therefore forms a molecular relay: adrenergic stimulation increases iron uptake; iron activates and stabilizes MSRA; MSRA supports PKA activity; and PKA promotes lipolysis, thermogenesis and adipose browning.

Breaking the pathway changed cachexia

The crucial test came from disrupting MSRA.

The researchers crossed pancreatic cancer–prone mice with animals lacking MsrA. The tumors still developed, but the hosts responded differently.

Loss of MsrA reduced adipose tissue depletion, preserved adipocyte size and suppressed markers of thermogenesis. It also blunted the hypermetabolic state seen in tumor-bearing mice. Lean tissue and skeletal muscle were better preserved as well.

The effect could not simply be attributed to smaller cancers. In the experimental models, MsrA loss did not substantially alter primary tumor burden or metastatic incidence.

Instead, it changed how the host organism responded to the tumor.

In the spontaneous pancreatic cancer model, survival was analyzed in 35 mice with intact MsrA and 21 MsrA-deficient animals. Loss of the gene significantly prolonged overall survival. A separate orthotopic transplantation model produced the same direction of effect.

The researchers then restored normal MSRA specifically in adipose tissue of MsrA-deficient, tumor-bearing mice. This reversed the survival advantage and restored progressive weight loss and adipocyte wasting. A mutant MSRA unable to bind iron normally did not have the same effect.

That rescue experiment provides particularly strong evidence that iron-dependent MSRA activity in adipose tissue is an important causal component of cachexia in these models.

The work does not show that people with cancer cachexia should reduce their iron intake, nor does it establish MSRA inhibition as a treatment. The causal intervention experiments were performed predominantly in mice, while the human component relied on relatively small tissue cohorts. Genetic deletion in an experimental animal is also very different from pharmacologically inhibiting the pathway after cachexia has already begun.

There is another complication: the same iron–MSRA pathway contributes to normal cold-induced thermogenesis. Blocking it therapeutically could therefore affect normal temperature and energy regulation.

Still, the study shifts attention toward an early stage of systemic wasting. In pancreatic cancer models, adipose remodeling preceded substantial muscle loss, and an iron-sensitive redox enzyme proved capable of controlling much of that process.

Iron, in this setting, is not merely a nutrient used by metabolism. It becomes part of a signaling circuit that can turn an energy reserve into a source of additional energy expenditure.